Life-changing treatments for disorders of the immune system
Read MoreCyxone – an innovative clinical-stage biotech company
Cyxone develops disease modifying therapies for rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. With three unique programs, Cyxone is well positioned to deliver substantial benefits for patients, the health care system as well as for its shareholders.
CEO Tara Heitner comments
We look forward to a productive year with accelerated progress. We are working intensively with the study centers in the Covid-19 trial to ensure a swift inclusion process and successful study completion. We will soon finalize development plans for Rabeximod in rheumatoid arthritis and initiate start-up activities for the trial later in the year. I will do my utmost to ensure that Cyxone can take further leaps forward in the coming year, all in the interest of providing patients with better treatments and at the same time enhancing shareholder value.
Read MoreLatest News
-
BioStock article: Progress in Q4 sets tone for Cyxone in 2021
24 February 2021 -
BioStock article: Cyxone’s Covid-19 trial with Rabeximod initiated in Europe
22 January 2021 -
BioStock article: Regulatory approval and up-listing for Cyxone
14 December 2020
Press Releases
Interim Report 1 October to 31 December 2020
February 12, 2021 08:31 (CET)RegulatoryCyxone's presentation at Aktiedagen 27 January now published
January 28, 2021 09:12 (CET)Cyxone presents at Aktiedagen the 27 January 2021
January 20, 2021 09:20 (CET)